Literature DB >> 30586300

Exploring Tunable Hyperparameters for Deep Neural Networks with Industrial ADME Data Sets.

Yadi Zhou1, Suntara Cahya, Steven A Combs, Christos A Nicolaou, Jibo Wang, Prashant V Desai, Jie Shen.   

Abstract

Deep learning has drawn significant attention in different areas including drug discovery. It has been proposed that it could outperform other machine learning algorithms, especially with big data sets. In the field of pharmaceutical industry, machine learning models are built to understand quantitative structure-activity relationships (QSARs) and predict molecular activities, including absorption, distribution, metabolism, and excretion (ADME) properties, using only molecular structures. Previous reports have demonstrated the advantages of using deep neural networks (DNNs) for QSAR modeling. One of the challenges while building DNN models is identifying the hyperparameters that lead to better generalization of the models. In this study, we investigated several tunable hyperparameters of deep neural network models on 24 industrial ADME data sets. We analyzed the sensitivity and influence of five different hyperparameters including the learning rate, weight decay for L2 regularization, dropout rate, activation function, and the use of batch normalization. This paper focuses on strategies and practices for DNN model building. Further, the optimized model for each data set was built and compared with the benchmark models used in production. Based on our benchmarking results, we propose several practices for building DNN QSAR models.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30586300     DOI: 10.1021/acs.jcim.8b00671

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  7 in total

Review 1.  Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling.

Authors:  Linlin Zhao; Heather L Ciallella; Lauren M Aleksunes; Hao Zhu
Journal:  Drug Discov Today       Date:  2020-07-11       Impact factor: 7.851

Review 2.  Big Data and Artificial Intelligence Modeling for Drug Discovery.

Authors:  Hao Zhu
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-09-13       Impact factor: 13.820

3.  Artificial intelligence and inflammatory bowel disease: practicalities and future prospects.

Authors:  Johanne Brooks-Warburton; James Ashton; Anjan Dhar; Tony Tham; Patrick B Allen; Sami Hoque; Laurence B Lovat; Shaji Sebastian
Journal:  Frontline Gastroenterol       Date:  2021-12-10

4.  Industry-scale application and evaluation of deep learning for drug target prediction.

Authors:  Noé Sturm; Andreas Mayr; Thanh Le Van; Vladimir Chupakhin; Hugo Ceulemans; Joerg Wegner; Jose-Felipe Golib-Dzib; Nina Jeliazkova; Yves Vandriessche; Stanislav Böhm; Vojtech Cima; Jan Martinovic; Nigel Greene; Tom Vander Aa; Thomas J Ashby; Sepp Hochreiter; Ola Engkvist; Günter Klambauer; Hongming Chen
Journal:  J Cheminform       Date:  2020-04-19       Impact factor: 5.514

5.  Modeling Physico-Chemical ADMET Endpoints with Multitask Graph Convolutional Networks.

Authors:  Floriane Montanari; Lara Kuhnke; Antonius Ter Laak; Djork-Arné Clevert
Journal:  Molecules       Date:  2019-12-21       Impact factor: 4.411

6.  Revealing Adverse Outcome Pathways from Public High-Throughput Screening Data to Evaluate New Toxicants by a Knowledge-Based Deep Neural Network Approach.

Authors:  Heather L Ciallella; Daniel P Russo; Lauren M Aleksunes; Fabian A Grimm; Hao Zhu
Journal:  Environ Sci Technol       Date:  2021-07-25       Impact factor: 11.357

7.  Predictive modeling of estrogen receptor agonism, antagonism, and binding activities using machine- and deep-learning approaches.

Authors:  Heather L Ciallella; Daniel P Russo; Lauren M Aleksunes; Fabian A Grimm; Hao Zhu
Journal:  Lab Invest       Date:  2020-08-10       Impact factor: 5.662

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.